- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 800 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
| 12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 559 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
| 12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 676 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
| 06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 821 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
| 11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 425 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,110 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| ABCELLERA BIOLOGICS | 4,785 | -0,44 % | Why Did AbCellera's Stock Jump Over 7% After Hours? | ||
| ANAVEX LIFE SCIENCES | 8,130 | +1,02 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program | ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current... ► Artikel lesen | |
| VERACYTE | 31,400 | +0,64 % | Canaccord Genuity initiates Veracyte stock with Hold rating, $40 price target | ||
| ASCLETIS PHARMA | 1,070 | +7,00 % | Ascletis Pharma Inc.: Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity | - The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment... ► Artikel lesen | |
| BIOMEA FUSION | 1,585 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series | ||
| JASPER THERAPEUTICS | 2,540 | +1,20 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants | REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel... ► Artikel lesen | |
| ABSCI | 4,625 | 0,00 % | Absci climbs on clinical trial acceleration | ||
| LANTERN PHARMA | 4,040 | -1,46 % | RedChip Companies, Inc.: Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / October 3, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on the RedChip Small... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,610 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| QIAGEN | 42,105 | +0,59 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| NUVALENT | 97,18 | 0,00 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
| COGENT BIOSCIENCES | 15,860 | -2,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,880 | 0,00 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 189,94 | 0,00 % | Praxis Precision Medicines prices $525M public offering |
Das Unternehmen BENEVOLENTAI kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,087 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.